We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 29, 2018

Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib in Patients With BRAF-Mutant Melanoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial
Lancet Oncol 2018 Mar 21;[EPub Ahead of Print], R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, C Garbe, D Schadendorf, I Krajsova, R Gutzmer, V Chiarion-Sileni, C Dutriaux, JWB de Groot, N Yamazaki, C Loquai, LA Moutouh-de Parseval, MD Pickard, V Sandor, C Robert, KT Flaherty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading